Actemra PFS

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia.

Consumer Medicine Information (CMI) summary
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

Why am I using Actemra?

Actemra contains the active ingredient tocilizumab. Actemra for subcutaneous injection is used to treat active moderate to severe rheumatoid arthritis (RA) and giant cell arteritis (GCA) in adults, active moderate to severe polyarticular juvenile idiopathic arthritis (pJIA) in children over 2 years of age and active systemic juvenile idiopathic arthritis (sJIA) in children and adolescents, aged 1 year and over. For more information, see Section 1. Why am I using Actemra? in the full CMI.

What should I know before I use Actemra?

Do not use if you have ever had an allergic reaction to Actemra or any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I use Actemra? in the full CMI.

What if I am taking other medicines?

Some medicines may interfere with Actemra or it may interfere with other medicines. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

How do I use Actemra?

Follow all instructions given to your doctor or pharmacist carefully. They may differ from the information contained in this leaflet. Use Actemra exactly as your doctor has prescribed.
The recommended dose of Actemra is dependent on your weight and depends on what you are being treated for.
More instructions can be found in Section 4. How do I use Actemra? in the full CMI.

What should I know while using Actemra?

Things you should do
Tell your doctor immediately or go to accident and emergency if you develop symptoms of an allergic reaction.
Tell your doctor immediately if you develop an infection or have symptoms of an infection while you are using Actemra.
Tell your doctor if you become pregnant or if you are breast-feeding while taking Actemra.
If you are a woman of childbearing potential, you should use adequate contraception during and for several months after treatment with Actemra.
Driving or using machines
Be careful driving or operating machinery until you know how Actemra affects you.
Looking after your medicine
Store in a refrigerator (2°C to 8°C). Do not freeze.
The pre-filled syringe must always be kept in the carton to protect from light and keep dry.
Once removed from the refrigerator, the pre-filled syringe can be stored up to 2 weeks (14 days) at or below 30°C.
For more information, see Section 5. What should I know while using Actemra? in the full CMI.

Are there any side effects?

Serious side effects include the following: allergic reactions such as chest tightness, wheezing, difficulty breathing, severe dizziness or light-headedness, swelling of the face, lips, tongue, throat with difficulty breathing, skin rash, itching or hives (raised red patches of skin that are often very itchy), signs of an infection with or without fever, signs of tears of the stomach or intestines, liver disease, hepatitis and/or jaundice, signs of pancreatitis.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.
Active ingredient: tocilizumab (rch)
Consumer Medicine Information (CMI)
This leaflet provides important information about using Actemra. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Actemra.
Where to find information in this leaflet:

Why am I using Actemra?

Actemra contains the active ingredient tocilizumab.
Actemra belongs to a group of medicines called monoclonal antibodies.
Monoclonal antibodies are proteins which specifically recognise and bind to other unique proteins in the body.
Actemra for subcutaneous injection is used to treat active moderate to severe rheumatoid arthritis (RA) and giant cell arteritis (GCA) in adults.
Actemra is also used to treat active moderate to severe polyarticular juvenile idiopathic arthritis (pJIA) in children over 2 years of age and active systemic juvenile idiopathic arthritis (sJIA) in children and adolescents, aged 1 year and over. Some of the signs and symptoms of these conditions are caused by the actions of a protein called interleukin-6 receptor (IL-6R).
Actemra works by binding and blocking IL-6R thereby helping to relieve some of the signs and symptoms of these conditions. For patients with RA, Actemra can also prevent damage occurring to your joints.
There are different types of medicines used to treat RA, GCA, pJIA and sJIA. Your doctor, however, may have prescribed Actemra for another purpose.
Ask your doctor if you have any questions about why Actemra has been prescribed for you.
Actemra is not addictive.
This medicine is available only with a doctor's prescription.

What should I know before I use Actemra?

Warnings

Do not use Actemra if:

1. you are allergic to:

Actemra, any of the ingredients listed at the end of this leaflet, or any other recombinant human or humanised antibodies or proteins that are of hamster origin
Always check the ingredients to make sure you can use this medicine.
Symptoms of an allergic reaction may include:
chest tightness, wheezing or difficulty breathing
severe dizziness or light-headedness
swelling of the face, lips, tongue, throat or other parts of the body with difficulty breathing
skin rash, itching or hives (raised red patches of skin that are often very itchy)
or

2. you have an active, severe infection

Actemra can reduce your body's ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection. This may be important if you have diabetes or diverticulitis (which increase your risk of infection).
Tell your doctor if you think you have an infection or have symptoms of an infection. Signs of an infection, with or without fever include:
sweating or chills,
feeling very tired
cough
shortness of breath
muscle aches
weight loss
warm, red, or painful skin or sores on your body
blood in phlegm
diarrhoea or stomach ache
persistent headaches
burning when you urinate or urinating more often than normal.

Check with your doctor if:

you have any other health problems, especially the following:
liver disease such as viral hepatitis or other liver problems
Your doctor will monitor your liver function closely before and during your treatment with Actemra.
HIV or AIDs
tuberculosis
diverticulitis or ulcers in your intestine
a low white blood cell count (white blood cells that help the body fight off infections)
a low platelet count (blood cells that help with blood clotting and stop bleeding)
diabetes
cancer
heart problems
raised blood pressure
high cholesterol or triglycerides
kidney disease
have a condition which affects your nervous system, such as multiple sclerosis or
neuropathy
you are planning to have a vaccination or have recently had a vaccination
Certain types of vaccines should not be given while using Actemra.
During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Tell your doctor if you are pregnant or intend to become pregnant.
Women of childbearing potential should be advised to use adequate contraception during and for several months after treatment with Actemra. Actemra should not be used during pregnancy as Actemra may harm your unborn baby. However if there is a need to take Actemra when you are pregnant, your doctor will discuss the benefits and risks to you and the unborn baby.
Tell your doctor if you are breast-feeding or plan to breast-feed
It is not known whether Actemra passes into breast milk. It is recommended that you discontinue breast-feeding while you are treated with Actemra.

Use in Children

Actemra given as a subcutaneous injection to patients below 18 years of age with conditions other than pJIA and sJIA has not been studied.
Actemra given as a subcutaneous injection in pJIA in children under the age of 2 and sJIA in children under the age of 1 has not been studied.
Actemra must not be given to children weighing less than 10 kg.

What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.
These medicines increase your risk of side effects with Actemra:
other biological medicines for RA. e.g. infliximab, adalimumab, etanercept, certolizumab pegol, golimumab anakinra, abatacept, rituximab.
It is unknown how Actemra interacts with these medicines. You may have an increased risk of infection. You should not use Actemra with other biological medicines for RA.
vaccines
Certain types of vaccines should not be given while receiving Actemra. You may have an increased risk of infection.
Actemra may reduce the amount of some medicines that require close monitoring to ensure drug levels are maintained. You may need to use different amounts of your medicine, or you may need to take different medicines. Your doctor will advise you. E.g.:
warfarin, a medicine used to prevent blood clots
cyclosporin, a medicine used after organ transplants
atorvastatin and simvastatin, medicines used to reduce cholesterol levels
calcium channel blockers, such as amlodipine, which are used to treat raised blood pressure
theophylline, a medicine used to treat asthma
phenytoin, a medicine used to treat convulsions
benzodiazepines, such as diazepam, which are used to treat anxiety
Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Actemra.

How do I use Actemra?

Follow all instructions given to your doctor or pharmacist carefully. They may differ from the information contained in this leaflet. Use Actemra exactly as your doctor has prescribed.

How much to inject

Adult patients with RA and GCA
The recommended dose of Actemra to treat RA or GCA is 162 mg injected once a week. For GCA, your doctor may prescribe a lower dose of 162 mg every 2 weeks.
Actemra must be used on the same day each week. Choose the day of the week that best fits your schedule.
The syringe is designed to deliver 162 mg per injection when used according to the instructions in this leaflet.
Your doctor will test your blood to help guide your treatment. If you experience certain changes in your blood tests, your doctor may decide to reduce the frequency of dosing to 162 mg every 2 weeks.
For RA, Actemra is usually given in combination with methotrexate (MTX). However you may use Actemra on its own if your doctor determines that initial treatment with MTX is inappropriate or unsuccessful.
For GCA, Actemra is initially given in combination with a glucocorticoid medicine (such as prednisone). Over the period of treatment, deding on your response to Actemra, your doctor will adjust the dose of the glucocorticoid with the aim to reduce it over time.
Children and adolescents with pJIA or sJIA (aged 12 and over)
The usual dose of Actemra depends on the patient's weight.
Children and adolescents with pJIA (aged 1 and over)
If the patient weighs less than 30 kg
The dose is 162 mg (the content of 1 pre-filled syringe) once every 3 weeks
If the patient weighs 30 kg or more
The dose is 162 mg (the content of 1 pre-filled syringe) once every 2 weeks
Children and adolescents with sJIA (aged 1 and over)
If the patient weighs less than 30 kg
The dose is 162 mg (the content of 1 pre-filled syringe) once every 2 weeks
If the patient weighs 30 kg or more
The dose is 162 mg (the content of 1 pre-filled syringe) once every week
Actemra must not be given to children less than 10 kg.
The increasing body weight of a child initially under 30kg should be checked regularly. This is because there is a risk of underdose for this medicine if the frequency of administration does not increase from every 3 weeks to every 2 weeks for pJIA patients (or every 2 weeks to once every week for sJIA patients) as the child grows from under to over 30 kg body weight.

How to inject Actemra

Actemra is administered by subcutaneous injection. This means it is injected with a short needle into the fatty tissue just under the skin.
Serious allergic reactions can occur with Actemra injections.
At least the first injection of Actemra will be given under the supervision of your healthcare provider in a healthcare facility that can manage these reactions. After your first injection, your doctor may discuss with you whether it would be appropriate for you to inject the next Actemra injection yourself at home, in which case, you or a caregiver would be instructed on how to give the injection and what to do if you experience symptoms of an allergic reaction.
Directions for self-injection
You should read these directions from beginning to end before starting to inject so that you are familiar with each step of the procedure. These instructions must be carefully followed. Consult with your healthcare provider if you require further instructions. These instructions do not replace the instructions from your healthcare provider.
Your healthcare provider should show you how to prepare and inject properly before you inject for the first time. Ask them any questions you may have.
Do not attempt to administer an injection until you are sure that you understand how to self-inject.
It is important to remain under your doctor's care while using Actemra. It is recommended you have someone else present when you self-inject Actemra in case you experience any symptoms of a serious allergic reaction described under Section 5. What should I know while using Actemra?.
The syringe is for single use only and should be safely discarded after use.

How to inject using the syringe

The syringe components:

462219.png

Do not use if the syringe appears to be damaged.
Do not use if the medicine is cloudy, hazy, discoloured or contains particles.
Do not shake the syringe.
Do not try to open the syringe or take it apart.
Do not remove the needle cap until you are ready to inject.
Do not inject through clothing covering the skin.
Do not re-use the same syringe.
Do not touch the syringe trigger fingers as this may damage the syringe.
Gather what you will need:
Included in the pack
Pre-filled syringe
Not included in the pack
Alcohol pad
Sterile cotton ball or gauze
Puncture-resistant container (also called a "sharps" container) for safe disposal of the needle cap and used syringe.
Find a well-lit, clean, flat surface such as a table.
Step 1. Visually check the syringe
Take the carton containing the syringes out of the refrigerator and remove one syringe from the carton. Return the remaining syringes in the carton to the refrigerator.
Do not shake.
If there is foam in the medicine, put the syringe back in the carton in the refrigerator for use another time and take a new syringe from the refrigerator.
Visually examine the syringe, as well as the medicine through the viewing window. The injection should be clear and colourless or slightly yellow.
Do not use if the syringe appears to be damaged.
Do not use if the medicine is cloudy, hazy, discoloured or contains particles.
Check the expiration date on the carton and syringe to make sure that it has not expired. The expiry date refers to the last day of that month.

462220.png

Do not use the syringe if the expiration date has passed.
Do not remove the syringe needle cap until step 5.
Step 2. Allow the syringe to adjust to room temperature
Place the syringe on a clean flat surface. Allow the syringe to warm up to room temperature which should take 25 to 30 minutes.
Do not warm up the syringe in any other way.
Step 3. Clean your hands
Wash your hands with soap and water. Cleanliness is vital during the injection procedure.
Step 4. Choose and prepare an injection site
The front of your thigh or your abdomen below the navel (belly button), except for the 2-inch (5 cm) area around your navel are the recommended injection sites (See Figure B). If a caregiver is giving the injection, the outer area of the upper arms may also be used.
Use a different place each time you give yourself an injection. The new injection site should be at least 3 centimetres away from your previous injection site.
Fig. B

image3.png

Do not inject into areas that could be irritated by a belt or waistband. Do not inject into moles, scars, bruises, or areas where the skin is tender, red, hard or not intact.
Clean the chosen injection area using the alcohol pad, to reduce the risk of infection. Let the skin dry for approximately 10 seconds. Be sure not to touch the cleaned area prior to the injection. Do not fan or blow on the cleaned area.

462222.png

Step 5. Remove needle cap
Do not hold the syringe by the plunger while removing the needle cap.
Hold the needle shield of the syringe firmly with one hand and pull off the needle cap with the other hand. If you cannot remove the needle cap you should request the help of a caregiver or contact your healthcare provider.

462221.png

Do not touch the needle or let it touch any surface.
You may see a drop of liquid at the end of the needle. This is normal and will not affect your dose.
There may be a small air bubble in the ACTEMRA pre-filled syringe. You do not need to remove it.
Throw away the needle cap in the sharps container.
Once the needle cap is removed, the syringe should be used immediately, to prevent the medicine from drying out and blocking the needle. If it is not used within 5 minutes, the syringe should be disposed of in the sharps container and a new syringe should be used.
Do not re-attach the needle cap after removal.
Step 6. Give the injection
Hold the syringe comfortably in your hand. Be careful not to touch the syringe trigger fingers as this may damage the syringe.
To be sure the needle can be inserted correctly under the skin, pinch a fold of loose skin at the clean injection site with your free hand.
Do not hold or push on the plunger while inserting the needle into the skin.
Insert the needle all the way into the pinched skin at an angle between 45° to 90° with a quick, firm action.

462226.png

It is important to choose the correct angle to ensure the medication is delivered under the skin (into fatty tissue), otherwise the injection could be painful and the medication may not work.
Then keep the syringe in position and let go of the pinch of skin.
Hold the syringe with two fingers under the flange (or "wings") and thumb on the plunger. Slowly inject all of the medicine by gently pushing the plunger all the way down.

462225.png

You must press the plunger all the way down to ensure that you get the full dose of medication and to ensure the trigger fingers are completely pushed to the side.
If the plunger is not fully depressed the needle shield will not extend to cover the needle when it is removed.
Once the plunger is pushed all the way down, keep pressing down on the plunger to be sure all of the medicine is injected before taking the needle out of the skin.
Keep pressing down on the plunger while you take the needle out of the skin at the same angle as inserted.

461808.png

Once the needle is removed completely from the skin, you can release the plunger. The needle will retract allowing the needle shield to protect the needle.

462223.png

If the needle is still exposed proceed carefully, and place the syringe into the sharps container to avoid injury with the needle (see Step 7).
If you see drops of blood at the injection site, you can press the sterile cotton ball or gauze over the injection site for approximately 10 seconds.
Do not rub the injection site.
Step 7. Safely dispose of the syringe
Do not try to re-cap your syringe.
Throw away used syringes in a sharps container.
Ask your healthcare provider or pharmacist for information about where you can get a sharps container or what other types of puncture-resistant containers you can use to safely dispose of your used syringes, if you do not have one.

462227.png

Do not throw away used syringes or the sharps container in household rubbish and do not recycle them.
Dispose of the full container as instructed by your healthcare provider or pharmacist.
Always keep the sharps container out of the reach of children.

When to use Actemra

The duration of treatment depends on how you are responding to the medicine. Your doctor will discuss this with you. Continue to use Actemra until your doctor tells you to stop.

If an adult with RA/GCA or a child or adolescent with pJIA or sJIA forgets to use Actemra

It is very important to use Actemra exactly as prescribed by your doctor. Keep track of your next dose.
For once a week Actemra dosing
If you missed your once a week Actemra dose and you remember within 7 days, you should skip the missed dose. Make sure you inject your next dose normally on the next scheduled day.
For example, if you forget your scheduled dose on Monday but you remember on Wednesday, you should skip your missed dose and inject the next dose as you would normally on the following Monday.
For fortnightly or every three week Actemra dosing
If you missed your fortnightly or every three week Actemra dose and you have remembered within 7 days of the dose you missed, you should inject the missed dose as soon as possible Inject the next dose as you would on the next scheduled day.
Do not give yourself two injections to make up for the injection that you missed.
If it has been more than 7 days since your missed dose, contact your doctor for advice.
If you are not sure when to inject your next dose, contact your doctor for advice.

If you are given too much Actemra

If you think that you or anyone else have had too much Actemra, you may need urgent medical care. You should immediately:
phone the Poisons Information Centre
(by calling 13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.
You should do this even if there are no signs of discomfort or poisoning.

What should I know while using Actemra?

Things you must do

Tell your doctor immediately or go to Accident and Emergency at your nearest hospital if:
you experience symptoms of a serious allergic reaction during or after receiving Actemra such as;
chest tightness, wheezing or difficulty breathing
severe dizziness or light-headedness
swelling of the face, lips, tongue, throat or other parts of the body with difficulty breathing
skin rash, itching or hives (raised red patches of skin that are often very itchy).
The reaction can occur even after multiple doses of Actemra. If you have experienced any allergic reaction symptoms after using Actemra, do not take the next dose until you have informed your doctor AND your doctor has told you it is safe to take the next dose.
Tell your doctor immediately if:

1. You develop an infection or have symptoms of an infection while you are using Actemra. Signs of an infection, with or without fever include:

sweating or chills,
feeling very tired
cough
shortness of breath
muscle aches
weight loss
warm, red, or painful skin or sores on your body
blood in phlegm
diarrhoea or stomach ache
persistent headaches
burning when you urinate or urinating more often than normal.

2. you develop severe blisters and bleeding in the lips, eyes, mouth, nose and genitals while you are using Actemra.

Skin cancer monitoring:
if you are at increased risk for skin cancer:
Regular skin examination is recommended if you are at increased risk for skin cancer.
Exposure to sunlight and UV light should be limited by wearing protective clothing and using sunscreen with a high protection factor.
Immunosuppressive medication (a medicine that reduces the activity of your immune system), such as Actemra, have an increased risk of developing skin cancer (melanoma and non-melanoma).
Tell all doctors, dentists and pharmacists who are treating you that you are receiving Actemra.
Tell your doctor if you become pregnant while taking Actemra.
Tell your doctor if you are breast-feeding while being treated with Actemra.
Tell your doctor if you feel Actemra is not helping your condition.
Be sure to keep all of your appointments and get follow-up blood tests done as ordered by your doctor so that your progress can be checked.
Blood tests/monitoring:
Liver enzymes:
If you have rheumatoid arthritis (RA) or giant cell arteritis (GCA), your doctor should do blood tests every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks. Your doctor will then decide on the frequency.
If you have polyarticular juvenile idiopathic arthritis (pJIA) or systemic juvenile idiopathic arthritis (sJIA), your doctor should do blood test at the time of second administration and every 4 to 8 weeks for pJIA and 2 to 4 weeks for sJIA.
Blood count:
If you have rheumatoid arthritis (RA) or giant cell arteritis (GCA), your doctor should do blood tests every 4 to 8 weeks after the start of therapy. Your doctor will then decide on the frequency.
If you have polyarticular juvenile idiopathic arthritis (pJIA) or systemic juvenile idiopathic arthritis (sJIA), your doctor should do blood tests at the time of second administration and every 4 to 8 weeks for pJIA and 2 to 4 weeks for sJIA.
Your doctor should do blood test levels according to the current clinical guidelines.
Cholesterol:
If you have RA and sJIA, your doctor will decide on the frequency of testing.
If you have pJIA, your cholesterol levels should be tested every 3 months while on Actemra.
Remind any doctor, dentist or pharmacist you visit that you are using Actemra.

Driving or using machines

Be careful driving or operating machinery until you know how Actemra affects you.
Actemra has not been shown to impair the ability to drive or operate machinery. However if you experience dizziness, a reported side effect, then you should not drive or operate machinery until it has resolved.

Looking after your medicine

Before injection
Store in a refrigerator (2°C to 8°C). Do not freeze.
Store the syringes in the carton to protect them from light and to keep them dry.
Once removed from the refrigerator, the pre-filled syringe can be stored up to 2 weeks (14 days) at or below 30°C. The unopened pre-filled syringe may be removed and returned to the refrigerator multiple times as long as the total length of time at or below 30°C is not more than 14 days. The pre-filled syringe must always be kept in the carton to protect from light and keep dry.
Do not use Actemra if the package is torn or shows signs of tampering.
Do not use Actemra after the expiry date which is stated on the carton and syringe labels after 'EXP'. The expiry date refers to the last day of that month.
After injection
The syringe is intended for single use only and must be discarded after the injection.
Dispose of the syringes in a sharps container as instructed by your doctor, nurse or pharmacist.
Do not put the used syringes in your normal household rubbish.
Keep it where young children cannot reach it.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date or if your doctor tells you to stop using Actemra, take it to any pharmacy for safe disposal. Do not use this medicine after the expiry date.

Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.
See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effects
What to do
Blood pressure related:
high blood pressure or hypertension (symptoms may include headache, dizziness, ringing in the ears)
Injection site reaction related:
skin redness
itchy skin
pain in the injection site
Stomach related:
constipation
General:
anxiety
difficulty sleeping
low potassium levels shown by blood tests
mouth ulcers
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effects
What to do
Allergic reaction related:
chest tightness, wheezing or difficulty breathing,
severe dizziness or light-headedness
swelling of the face, lips, tongue, throat or other parts of your body with difficulty breathing
skin rash, itching or (raised red
patches of skin that are often very itchy).
Infections:
signs of an infection, with or without fever: sweating or chills, feeling very tired, cough, shortness of breath, muscle aches, weight loss, warm, red, or painful skin or sores on your body, blood in phlegm, diarrhoea or stomach ache, persistent headaches, burning when you urinate or urinating more often than normal.
Severe blisters and bleeding in lips, eyes, mouth, nose and genitals.
Stomach and gut:
signs of tears (perforation) of the stomach or intestines such as fever and pain in the stomach area that does not go away, vomiting blood or material that looks like coffee grounds, bleeding from your rectum, and a change in your bowel habits
signs of inflamed pancreas (pancreatitis) including: upper stomach pain, abdominal pain that may spread to the back, generally feeling unwell/sick
Liver:
signs of liver disease, hepatitis and/or jaundice including: nausea, vomiting, loss of appetite, feeling generally unwell, fever, itching, yellowing of the skin and eyes, light coloured bowel motions, dark coloured urine.
Laboratory tests:
low white blood cell and platelet counts.
increase in certain liver function tests.
raised blood fat (cholesterol) levels.
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.
Call your doctor straight away if you notice any of these serious side effects.
Call your doctor straight away if you notice any of these serious side effects.
Call your doctor straight away if you notice any of these serious side effects.
Make sure you get all your follow-up blood tests done as ordered by your doctor.
Side effects in children and adolescents with pJIA and sJIA
Side effects in children and adolescents with pJIA and sJIA are generally similar to those in adults. Some side effects are seen more often in children and adolescents: inflamed nose and throat, headache, feeling sick (nausea) and lower white blood cell counts.
Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.
Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of this medicine.
Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

Product details

This medicine is only available with a doctor's prescription.

What Actemra contains

Active ingredient
(main ingredient)
tocilizumab (rch)
Other ingredients (inactive ingredients)
Actemra ® (AUST R 234034)
polysorbate 80
histidine
histidine hydrochloride monohydrate
arginine
arginine hydrochloride
methionine
water for injections
Actemra ® SC (AUST R 370315)
polysorbate 80
histidine
histidine hydrochloride monohydrate
arginine hydrochloride
methionine
water for injections
Do not take this medicine if you are allergic to any of these ingredients.

What Actemra looks like

Actemra is a clear to opalescent, colourless to pale yellow solution.
Australian Registration Numbers:
Actemra® 162mg/0.9mL pre-filled syringe AUST R 234034
Actemra® SC 162mg/0.9mL pre-filled syringe AUST R 370315
Actemra is available as a pre-filled pen (162mg/0.9mL) in packs of 1 and 4 pens, with the tradenames Actemra® and Actemra® SC.
Actemra is also available as a concentrated solution for intravenous infusion.

Who distributes Actemra

Roche Products Pty Limited
ABN 70 000 132 865
Level 8, 30-34 Hickson Road
Sydney NSW Australia
How to contact us
You can contact us at www.medinfo.roche.com/australia  or by scanning the below code:

461793.png

You can also call us on 1800 233 950.
This leaflet is for people in Australia only. If you are not in Australia, you can contact Roche/Genentech in your country at www.medinfo.roche.com .
This leaflet was prepared in November 2022.